Combined administration of A2A receptor antagonist and 5-HT1A/1B receptor agonist reverses neuroinflammation in the 6-OHDA model of Parkinson’s disease
Objective: To investigate whether in a model of Parkinson's Disease (PD), an early treatment with the serotonin 5-HT1A/1B receptor agonist eltoprazine and the adenosine A2A…The complementary relationship between zonisamide and istradefylline in treating patients with Parkinson’s disease
Objective: To investigate patients with Parkinson’s disease (PD) who received zonisamide and istradefylline at the same period. Background: Zonisamide and istradefylline are anti-PD drugs with…Efficacy of Tozadenant in Animal Models of Non-Motor Symptoms of Parkinson’s Disease
Objective: Investigate the potential of tozadenant (TOZ) to alleviate the non-motor symptoms of Parkinson's disease using multiple animal models. Background: TOZ is an oral, selective…Design and discovery of 1,2,4 triazole derivatives as adenosine A2A receptor antagonist against parkinson’s disease
Objective: In the present study, we intended to develop novel 1,2,4 triazole as potent A(2A)AR antagonists against parkinson’s disease. Background: Parkinson’s disease (PD) is a…Istradefylline improves motor symptoms in Parkinson’s disease: A meta-analysis
Objective: The aim of this meta-analysis was to provide strong evidence for the main and side effects of istradefylline on patients with Parkinson’s disease. Background:…Istradefylline improves not only motor symptoms but also sleep disturbance, daytime sleepiness, and QOL of Parkinson’s disease patients.
Objective: This study analyzed the clinical effectiveness of istradefylline in terms of sleep disturbance in Parkinson’s disease (PD) patients. Background: A selective adenosine A2A receptor…Caffeine as a Treatment for Parkinson’s Disease: A Randomized Controlled Trial (CafePD)
Objective: To assess the effects of caffeine on patients with Parkinson's disease. Background: Multiple studies have linked use of caffeine, an adenosine antagonist, to a…Istradefylline and Preladenant as adjuvant therapies for Patients with Parkinson’s disease
Objective: The aim of this meta-analysis is to synthesize evidence about the efficacy of the adenosine receptor antagonists (Istradefylline and Preladenant) for patients with Parkinson’s…Detailed evaluation of dyskinesias using multiple endpoints in a randomized, placebo-controlled trial of Parkinson’s disease patients with motor fluctuations
Objective: To analyze all dyskinesia data from a Phase 2b trial of fluctuating Parkinson patients in order to understand the overall impact a study drug…Regional differences in the results of a phase 2b study of tozadenant in Parkinson’s disease patients with motor fluctuations
Objective: To assess how the efficacy of tozadenant differed by region in a randomized, double-blind, placebo-controlled trial of Parkinson's disease patients with motor fluctuations. Background:…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.